(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of 12.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Voyager Therapeutics's revenue in 2025 is $60,485,000.On average, 5 Wall Street analysts forecast VYGR's revenue for 2025 to be $2,439,451,885, with the lowest VYGR revenue forecast at $524,036,144, and the highest VYGR revenue forecast at $3,527,698,433. On average, 5 Wall Street analysts forecast VYGR's revenue for 2026 to be $4,979,394,757, with the lowest VYGR revenue forecast at $524,036,144, and the highest VYGR revenue forecast at $8,851,064,538.
In 2027, VYGR is forecast to generate $4,181,000,514 in revenue, with the lowest revenue forecast at $524,036,144 and the highest revenue forecast at $6,795,868,933.